trending Market Intelligence /marketintelligence/en/news-insights/trending/c863tjzo98jpth-vnhpf2a2 content esgSubNav
In This List

Arcus Biosciences plans $100M IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Arcus Biosciences plans $100M IPO

Arcus Biosciences Inc. plans to offer up to $100 million of its common shares in an IPO.

The clinical-stage biopharmaceutical company focused on creating cancer immunotherapies has applied to list its common stock on the New York Stock Exchange under the symbol RCUS.

Arcus plans to use the net proceeds to fund the clinical development of its product candidates, drug discovery and optimization programs as well as other general corporate purposes.

Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Leerink Partners LLC are acting as joint book-running managers of the offering.